Filing Details

Accession Number:
0001346302-21-000002
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-12 16:02:36
Reporting Period:
2021-01-11
Accepted Time:
2021-01-12 16:02:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346302 Xeris Pharmaceuticals Inc XERS Pharmaceutical Preparations (2834) 203352427
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744027 Steven Prestrelski C/O Xeris Pharmaceuticals, Inc.
180 N. Lasalle Street, Suite 1600
Chicago IL 60601
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-01-11 10,000 $5.72 416,824 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. $5.7244 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.